Publications of Y. Genzel
All genres
Talk (122)
261.
Talk
A generic purification scheme for the production of human influenza vaccines derived from serum-free mammalian cell culture. Vaccine Technology, Puerto Vallarta, Mexico (2006)
262.
Talk
Chromatography-based purification of influenza A virus for the production of human whole-virion vaccines. ISPPP 2006 : 26th International Symposium on the Separation of Proteins, Peptides and Polynucleotides, Innsbruck, Austria (2006)
263.
Talk
Monitoring Energy Metabolism: The Challenge of Intracellular Metabolite Analysis of Mammalian Cells in Culture. 1st Max Planck Workshop on "Metabolomics", Magdeburg, Germany (2006)
264.
Talk
Mammalian cell culture for influenza vaccine production: physiology during cell growth and virus propagation phase. GVC/DECHEMA-Jahrestagungen 2006 mit 24. DECHEMA-Jahrestagung der Biotechnologen, Wiesbaden, Germany (2006)
265.
Talk
Influenza Vaccines: Challenges in Mammalian Cell Culture Technology. 19th ESACT Meeting, Harrogate, UK (2005)
266.
Talk
Amino acid analysis in mammalian cell culture based virus vaccine production processes. IICS : 17th annual International Ion Chromatography Symposium, Trier, Germany (2004)
Poster (131)
267.
Poster
Genetically engineered defective interfering particles of influenza A virus for antiviral treatment and vaccination. 32nd Annual Meeting of the Society for Virology (GfV), Ulm (Germany) (2023)
268.
Poster
Genetically engineered defective interfering particles of influenza A virus for antiviral treatment and vaccination. 8th European Congress of Virology, Gdańsk (Poland) (2023)
269.
Poster
Absolute quantification of viral proteins during single-round replication of vaccine producer cell lines. 32nd Annual Meeting of the Society for Virology (GfV) , Ulm (Germany) (2023)
270.
Poster
Absolute quantification of influenza A virus proteins during single-round replication in vaccine producer cell lines. 16th PEACe (Protein Expression in Animal Cells) Conference, Sitges (Spain) (2023)
271.
Poster
Influenza A virus OP7 defective interfering particles: Cell culture-based production and antiviral efficacy in vivo. Cell Culture Engineering (CCE) XVIII , Cancun (Mexico) (2023)
272.
Poster
A Scalable High-Yield Process for Production of Influenza A Virus Defective Interfering Particles and In Vivo Studies. Himmelfahrtstagung on Bioprocess Engineering 2023, Weimar (Germany) (2023)
273.
Poster
Influenza A Virus Chimeric OP7 Defective Interfering Particles: Cell Culture-based Production and In Vivo Antiviral Efficacy. 32nd Annual Meeting of the Society for Virology (GFV), Ulm (Germany) (2023)
274.
Poster
Production of a fusogenic oncolytic rVSV-NDV virus in perfusion processes. Vaccine Technology VIII, Sitges (Spain) (2022)
275.
Poster
Towards the production of a fusogenic oncolytic rVSV-NDV virus in perfusion mode. 27th ESACT Meeting, Lisbon (Portugal) (2022)
276.
Poster
Production of a fusogenic oncolytic VSV-NDV virus: cell-line screening and process development in small-scale suspension cultures. Advancing Manufacture of Cell and Gene Therapies VII, Coronado, CA (USA) (2022)
277.
Poster
Production of influenza A virus-derived defective interfering particles for antiviral therapy in a high cell density perfusion cultivation. 27th ESACT Meeting, Lisbon (Portugal) (2022)
278.
Poster
Absolute quantification of viral proteins during single-round replication of MDCK suspension cells. Proteomic Forum 2022, Leipzig (Germany) (2022)
279.
Poster
Long-Term Propagation of Influenza A Virus and Its Defective Interfering Particles: Analyzing Dynamic Competition to Select Antiviral Candidates. Vaccine Technology VIII, Sitges (Spain) (2022)
280.
Poster
Semi-Continuous propagation of Influenza A virus and its defective interfering particles: Analyzing the dynamic competition to select antiviral candidates. 27th ESACT Meeting, Lisbon (Portugal) (2022)